Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

KKairos Pharma, LTD.

EconomyAI buildoutMarket MapFundsWatchlist
Log in
K

Kairos Pharma, LTD.

  • Overview
  • Financial statements
  • Metrics
    • Revenue & profit
    • Revenue by segment
    • Launches
    • Revenue concentration
    • Margins
    • Contracted revenue
    • Off-balance-sheet commitments
    • Cash flow
    • Cash & debt
    • Earnings per share
    • P/E ratio
    • Share count & dilution
  • Quarterly earnings
  • Burn Rate
  • Similar companies
  • News
  • Insider Transactions
Loading financial graphs

Metrics

Revenue & profit
Revenue by segment
Margins
Contracted revenue
Cash flow
Cash & debt
Earnings per share
Share count & dilution

Metrics

Compare cash generated by the business, spending on long-lived assets, and what remains afterward.Formula: Free cash flow = operating cash flow − capital expenditures
$
2025202320242025-3M-2M-1M0
      Latest period 2025. Operating cash flow -3.4M.
      Operating cash flowCapexFree cash flow
      Compare the company’s cash cushion with its borrowings. Negative net cash means debt is greater than cash.Formula: Net cash = cash − debt
      2026202320242025202601M2M3M4M5M
          Latest period 2026. Cash 2.6M.
          CashDebtNet cash
          Profit for each share over the trailing 12 months, adjusted for stock splits.Formula: Earnings available to common shareholders ÷ weighted-average shares
          $/shareUsing split history cached 2026-09-23; assuming no new splits
          2025202320242025-2.00-1.000.001.00
            • Earnings period 2023-01-01 to 2023-12-31. Shares as of 2023-12-31: 10,562,640 source shares.
            • Earnings period 2024-01-01 to 2024-12-31. Shares as of 2024-12-31: 13,736,597 source shares.
            • Earnings period 2025-01-01 to 2025-12-31. Shares as of 2025-12-31: 20,821,353 source shares.
            Latest period FY 2025. EPS (TTM) -1.83.
            EPS (TTM)
            How much investors pay for each dollar of the company’s yearly earnings. It is not useful when the company has no profit.Formula: Share price ÷ trailing 12-month EPS
            Using split history cached 2026-09-23; assuming no new splits
            Security type not verifiedMissingSecurity type not verifiedMissingSecurity type not verifiedMissing20252023202420250x0.2x0.4x0.6x0.8x1x
            • FY 2023: Security type not verified
            • FY 2024: Security type not verified
            • FY 2025: Security type not verified
            • Earnings period 2023-01-01 to 2023-12-31. Shares as of 2023-12-31: 10,562,640 source shares.
            • Earnings period 2024-01-01 to 2024-12-31. Shares as of 2024-12-31: 13,736,597 source shares.
            • Earnings period 2025-01-01 to 2025-12-31. Shares as of 2025-12-31: 20,821,353 source shares.
            Latest period FY 2025. P/E ratio Missing.
            P/E ratio
            See how the number of shares changes over time. More shares can mean each existing share owns a smaller slice of the company.Formula: Outstanding shares = issued shares − treasury shares Share-count growth = (current shares ÷ previous shares − 1) × 100%
            Stock split history may be out of date.
            2026202320242025202605M10M15M20M
                Latest period 2026. Shares outstanding 21.4M. Class detail unavailable 21.4M.
                Class detail unavailable